Xiaodong Wang

Dr. Xiaodong Wang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
XWXiaodong Wang
Xiaodong Wang
JWJunjie Wang
Junjie Wang
QWQianqian Wang
Qianqian Wang
GDGouping Ding
Gouping Ding
YHYiping Huang
Yiping Huang
YFYeqian Feng
Yeqian Feng
Immune checkpoint inhibitors (ICIs) can elicit durable remissions, yet most solid tumors show primary non-response or acquired resistance because the tumor microenvironment (TME) limits T-cell priming, trafficking and effector fitness. Cytokines orchestrate these barriers by shaping spatial immune architecture, regulating suppressive myeloid programmes and inducing inhibitory ligands such as PD-L1. In this Review, we synthesize mechanistic and clinical evidence and propose a push-pull framework for cytokine modulation during checkpoint blockade: locally amplifying Th1/CTL-supporting signals (IL-2/IL-12/IL-15 and type I/II interferons) while selectively attenuating dominant suppressive circuits (TGF-β, IL-6/STAT3, IL-8-CXCR1/2, IL-10 and TNF-driven exhaustion). We critically contrast successful and failed cytokine-ICI combinations, highlighting how systemic exposure, network redundancy and counter-regulatory feedback have constrained several engineered agonists and explain why certain blockade strategies can improve efficacy while reducing immune-related toxicity. We discuss next-generation solutions-tumor-activated pro-cytokines, intratumoral gene delivery and immunocytokines-that concentrate activity within resistant niches and widen the therapeutic window. Finally, we outline actionable biomarkers, including transcriptomic signatures, plasma cytokine kinetics, myeloid/neutrophil metrics and spatial TME profiling, to stratify patients and guide dosing, sequencing and adaptive add-on strategies. Rational, biomarker-guided cytokine modulation offers a path to convert immune-excluded tumors into durable ICI responders.

7 February 2026 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JWJunjie Wang
Junjie Wang
QWQianqian Wang
Qianqian Wang
GDGouping Ding
Gouping Ding
YHYiping Huang
Yiping Huang
YFYeqian Feng
Yeqian Feng
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis

25 August 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
GDGouping Ding
Gouping Ding
JHJing He
Jing He
YHYiping Huang
Yiping Huang
QWQianqian Wang
Qianqian Wang
This bibliometric analysis maps global research trends on PARP inhibitors (PARPis) in ovarian cancer from January 2021 to May 2025, utilizing 1,434 publications retrieved from the Web of Science Core Collection. Employing Bibliometrix, VOSviewer, and CiteSpace, the study quantifies contributions across countries, institutions, authors, and research foci. Key findings reveal the United States (440 publications) and China (352) as leading producers, with UNICANCER (287 publications) and Memorial Sloan Kettering Cancer Center (61) as top institutions. Keyword clustering identified six research themes: PARPi resistance mechanisms (Cluster 1, red) emerged as the dominant focus, followed by immunotherapy combinations for platinum-resistant disease (Cluster 2, green), maintenance therapy (Cluster 3, blue), BRCA mutations (Cluster 4, yellow), applications beyond ovarian cancer (Cluster 5, purple), and anti-angiogenic mechanisms (Cluster 6, light blue). Temporal analysis highlighted an evolution from foundational research (e.g., DNA repair pathways) toward clinical translation (e.g., maintenance therapy optimization). Notable citation bursts surrounded clinical milestones, including the SOLO1 trial’s 7-year overall survival data (burst strength: 23.99), underscoring the field’s emphasis on survival outcomes. Critical gaps persist in understanding resistance mechanisms and developing immuno-combination strategies, which constituted only 4.8% of keyword frequency. The study underscores the need for intensified research into resistance mitigation and transnational collaboration, particularly between established Euro-American networks and emerging East Asian hubs, to address therapeutic challenges and optimize clinical impact.

17 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JHJing He
Jing He
GDGouping Ding
Gouping Ding
YTYixuan Tang
Yixuan Tang
QWQianqian Wang
Qianqian Wang
This large-scale bibliometric analysis maps the global research landscape of predictive biomarkers for immune checkpoint inhibitors (ICIs) from 2011 to 2025. Leveraging 9,075 publications from the Web of Science Core Collection, we used co-citation, co-authorship, and keyword co-occurrence analyses to quantify publication dynamics, collaborative networks, and conceptual evolution. China produced the most publications (1,923, a country-level count reflecting multi-national co-authorship), while the United States led in influence as reflected by high-impact institutions (e.g., MD Anderson Cancer Center) and prolific authors (e.g., Kurzrock R, H-index 116). The strongest international collaboration was between the USA and China (276 co-authored publications). Thematic evolution revealed a paradigm shift from reliance on single biomarkers (e.g., PD-L1, tumor mutational burden [TMB]) toward integrated multi-omics signatures that incorporate tumor microenvironment features and advanced computational approaches. Keyword analysis highlighted artificial intelligence (n = 640), radiomics, and liquid biopsy as emerging frontiers. Notably, gastroesophageal junction cancers exhibited the strongest citation burst (strength = 11.53), highlighting unresolved tumor-specific controversies such as the predictive validity of PD-L1 in this setting. However, significant translational barriers remain: lack of biomarker assay standardization, high analytical variability (e.g., differing PD-L1 immunohistochemistry clones and inconsistent TMB cutoff thresholds), and insufficient clinical validation. This study provides an evidence-based overview to guide future research toward multi-omics integration, prospective validation, and cross-disciplinary collaboration, thereby advancing precision immuno-oncology.

26 February 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
QWQianqian Wang
Qianqian Wang
GDGouping Ding
Gouping Ding
JWJunjie Wang
Junjie Wang
YFYeqian Feng
Yeqian Feng
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract